IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 66.56

Change

+0.11 (+0.16)%

Market Cap

N/A

Volume

0.17M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.57 (+0.41%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

+0.15 (+0.23%)

USD 2.62B
FXH First Trust Health Care AlphaD..

+0.21 (+0.20%)

USD 1.09B
XHE SPDR® S&P Health Care Equipme..

+0.55 (+0.62%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.04 (+0.18%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.04 (-0.12%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.28 (+0.31%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.11 (+0.37%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.07 (+0.11%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.01 (+0.03%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.70% 90% A- 57% F
Dividend Return 1.50% 94% A 25% F
Total Return 9.20% 90% A- 52% F
Trailing 12 Months  
Capital Gain 8.63% 90% A- 60% D-
Dividend Return 1.51% 94% A 25% F
Total Return 10.14% 90% A- 55% F
Trailing 5 Years  
Capital Gain 23.99% 52% F 63% D
Dividend Return 8.82% 95% A 26% F
Total Return 32.80% 67% D+ 58% F
Average Annual (5 Year Horizon)  
Capital Gain 4.40% 48% F 49% F
Dividend Return 5.77% 48% F 46% F
Total Return 1.37% 100% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 15.41% 71% C- 66% D+
Risk Adjusted Return 37.47% 67% D+ 52% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.